In the press

Matthew Read comments on possible clean exit for USF in Investment Week

Biotech trusts top performance charts in February

Matthew Read comments on USF’s wind-down and possible buyer in Robin Amos’ article:

“With USF in wind-down, a clean exit with greater certainty over the proceeds, rather than an earn-out arrangement, also has to be preferable at this stage. That said, regulatory approval could take up to five months and while the progress on due diligence is encouraging, without an agreed price or binding contract, there is still considerable uncertainty,”

Read the article here